Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Gut microbiome correlates of response and toxicity following anti CD19 CAR T cell therapy

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies - Kampouri - 2023 - Transplant Infectious Disease - Wiley Online Library

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy - ScienceDirect

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Advancing CAR T cell therapy through the use of multidimensional omics data

INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy